Abstract 3197
Background
Cardiac sarcoma is a rare tumor. Currently, there is a lack of data on the genomic profiling in Chinese cardiac sarcoma patients. In this study, we analyzed the genomic alterations and prognostic biomarkers of this kind of patients.
Methods
Total FFPE samples of 26 cardiac sarcoma patients who received operation during 2010 to 2018 were enrolled in this study. FFPE samples from these patients were collected for WES (Whole Exome Sequencing). Genomic alterations including single base substitution, copy number variations, gene fusions and rearrangement were assessed. Tumor mutational burden (TMB) was also analyzed by NGS algorithm.
Results
The cohort of 26 cardiac sarcoma patients included 13 males and 13 females with a median age of 54 (range 27-68). Patients were followed up for 8 years (10 patients) or until patients died (16 patients). The median overall survive (OS) was 14 months. This cohort included 18 angiosarcomas (AS), 6 intimal sarcomas (IS), 1 liposarcoma (LPS) and 1 synovial sarcoma (SS). The most commonly altered genes were KDR (35%), MDM2 (31%), FRS2 (27%), KMT2D (23%), CKD4 (23%), GLI1 (23%) and TERT (23%). Several druggable genomic alterations including amplification of CDK4 (6/26), KIT (5/26), KDR (2/26), PDGFRA (2/26), ERBB3 (1/26), and mutations of BRAF (1/26), BRCA1 (1/26) and PTEN (1/26) were found. AS patients with alterations of TP53, TRMT10C, ALMS1, CCDC157, CCNJL, KIAA2026 or OSBPL7 gene had a poor prognosis with a median OS of 3 months, while AS patients without alterations of any those genes had a median OS of 21 months. Interestingly, MDM2 amplification was only found in IS and LPS, but not in AS, which was confirmed by FISH analysis. The median TMB was 29 muts/Mb (2.3-56.5 muts/Mb) in this cohort.
Conclusions
Our study firstly revealed the genomic profiling of Chinese cardiac sarcoma patients. Several genes may be relevant with prognosis in AS, and MDM2 amplification may be a potential biomarker to distinguish between different subtypes. Most of the patients (92.3%) presented high TMB value which may potentially benefitted to immunotherapy. Due to limited number of patients, the correlation of gene mutations with clinical features need to be further analyzed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5239 - Treatment patterns and outcomes for patients (pts) with anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer (NSCLC) in US clinical practice
Presenter: Matthew Krebs
Session: Poster Display session 1
Resources:
Abstract
5595 - Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?
Presenter: Saadettin Kilickap
Session: Poster Display session 1
Resources:
Abstract
5840 - Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase 2 clinical trial – Updated progression-free survival, overall survival and mechanisms of resistance
Presenter: Sebastian Michels
Session: Poster Display session 1
Resources:
Abstract
1905 - NTRK1-3 Genomic Fusions in Non-Small Cell Lung Cancer (NSCLC) Determined by Comprehensive Genomic Profiling
Presenter: Sai-Hong Ou
Session: Poster Display session 1
Resources:
Abstract
3016 - Preferential expression of the affected MET allele in lung carcinomas with heterozygous MET exon 14 skipping mutations: implications for clinical testing
Presenter: Evgeny Imyanitov
Session: Poster Display session 1
Resources:
Abstract
4120 - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew G Krebs
Session: Poster Display session 1
Resources:
Abstract
3764 - Patients with metastatic non-small cell lung cancer and targetable molecular alterations in Germany. Treatment and first outcome data from the prospective German Registry Platform CRISP (AIO-TRK-0315)
Presenter: Frank Griesinger
Session: Poster Display session 1
Resources:
Abstract
4070 - Crizotinib vs Platinum-based Chemotherapy as First-line Treatment for Advanced Non-small Cell Lung Cancer with Different ROS1 Fusion Variants
Presenter: Haiyan Xu
Session: Poster Display session 1
Resources:
Abstract
5528 - Genomic and clinical characterization of Non-small cell lung cancer (NSCLC) patients harboring mutations in FGFR2 and FGFR3
Presenter: Matthias Scheffler
Session: Poster Display session 1
Resources:
Abstract
3779 - The expression of HER2-gene polymorphisms -1985G>T and P1170A C>G and their association with the risk of development of lung adenocarcinoma
Presenter: Ivan Aleric
Session: Poster Display session 1
Resources:
Abstract